<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2803245123
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ABRYSVO
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RSV SUBGROUP A STABILISED PREFUSION F,RSV SUBGROUP B STABILISED PREFUSION F
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        60,60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        816.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Manufacturing Belgium N.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Manufacturing Belgium N.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07BX
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Abrysvo is a vaccine to prevent lung (respiratory tract) disease caused by a virus called respiratory syncytial virus (RSV). Abrysvo is given to:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pregnant individuals to protect their infants from birth through 6 months of age</p><p>or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; individuals 60 years of age and older.</p><p>&nbsp;</p><p>RSV is a common virus which, in most cases, causes mild, cold-like symptoms such as a sore throat, cough or a blocked nose. However, in young infants RSV can cause serious lung problems. In older adults and people with chronic medical conditions, RSV can worsen illnesses such as chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF). RSV can lead to hospitalisation in severe cases and in some cases it can be fatal.</p><p>&nbsp;</p><p><strong>How Abrysvo works</strong></p><p>This vaccine helps the immune system (the body&rsquo;s natural defences) to make antibodies (substances in the blood that help the body fight infections) which protect against lung disease caused by RSV. In pregnant individuals who are vaccinated between weeks 24 and 36 of pregnancy, these antibodies are passed to the infant through the placenta before birth which protects infants when they are at most risk from RSV.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Abrysvo</strong><strong> should not be given</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to the active substances or any of the other ingredients of this vaccine (listed in section&nbsp;6).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before you are given this vaccine</p><ul><li>if you have ever had a severe allergic reaction or breathing problems after you received any other vaccine injection or after you were given Abrysvo in the past.</li><li>if you are feeling nervous about getting the vaccine or have ever fainted after any injection. Fainting can happen before or after any injection</li><li>if you have an infection with a high fever. If this is the case, then vaccination will be postponed. There is no need to delay vaccination for a minor infection, such as a cold, but talk to your doctor first.</li><li>if you have a bleeding problem or bruise easily.</li><li>if you have a weakened immune system which may prevent you from getting the full benefit from Abrysvo.</li><li>if you are less than 24 weeks pregnant.</li></ul><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before you are given Abrysvo.</p><p>&nbsp;</p><p>As with any vaccine, Abrysvo may not fully protect all those who receive it.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Abrysvo is not recommended in children and young people below 18 years of age except during pregnancy (see &lsquo;Pregnancy&rsquo; section below).</p><p>&nbsp;</p><p><strong>Other medicines and </strong><strong>Abrysvo</strong></p><p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines or have recently received any other vaccine.</p><p>&nbsp;</p><p>Abrysvo may be given at the same time as a flu vaccine. A gap of at least two weeks is recommended between administration of Abrysvo and administration of a vaccine against tetanus, diphtheria and acellular pertussis (whooping cough).</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Pregnant individuals can be given this vaccine in the late second or third trimester (weeks 24 to 36). Talk to your doctor or nurse for advice before getting this vaccine if you are breast-feeding.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Abrysvo is unlikely to affect your ability to drive or use machines.</p><p>&nbsp;</p><p><strong>Abrysvo contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You will be given one injection of 0.5&nbsp;mL into a muscle of your upper arm.</p><p>&nbsp;</p><p>If you have any questions on the use of Abrysvo, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all vaccines, this vaccine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p><strong>&nbsp;</strong></p><p><strong>Rare</strong> (may affect up to 1 in 1&nbsp;000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guillain-Barr&eacute; syndrome (a neurological disorder that usually starts with pins and needles and weakness of the limbs and may progress up to paralysis of part or all of the body).</p><p><strong>&nbsp;</strong></p><p><strong>Very rare</strong> (may affect up to 1 in 10&nbsp;000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions - signs of an allergic reaction include swelling of the face, lips, tongue or throat, hives, difficulty breathing or swallowing and dizziness. See also section&nbsp;2.</p><p>&nbsp;</p><p>Tell your doctor immediately if you notice signs of these serious side effects.</p><p>&nbsp;</p><p><strong>The following side effects were reported in pregnant individuals</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very common</strong> (may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain where the injection is given</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain (myalgia).</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness where the injection is given</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling where the injection is given.</p><p>&nbsp;</p><p>No side effects were reported in infants born to vaccinated mothers.</p><p>&nbsp;</p><p><strong>The following side effects were reported in </strong><strong>individuals 60 years of age and older</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very common</strong> (may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain where the injection is given</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness where the injection is given</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling where the injection is given.</p><p><strong>&nbsp;</strong></p><p><strong>Rare</strong> (may affect up to 1 in 1&nbsp;000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guillain-Barr&eacute; syndrome (see Serious side effects, above).</p><p>&nbsp;</p><p><strong>Very rare</strong> (may affect up to 1 in 10&nbsp;000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions (see Serious side effects, above).</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>To report side effects:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:378px"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:378px"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&ordm;C - 8&ordm;C).</p><p>&nbsp;</p><p>Do not freeze. Discard if the carton has been frozen.</p><p>&nbsp;</p><p>After reconstitution Abrysvo should be administered immediately or within 4 hours if stored between 15&deg;C and 30&deg;C. Do not freeze.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are:</p><p>RSV subgroup A stabilised prefusion F antigen<sup>1,2</sup> 60&nbsp;micrograms</p><p>RSV subgroup B stabilised prefusion F antigen<sup>1,2</sup> 60&nbsp;micrograms</p><p>(RSV antigens)</p><p><sup>1</sup>glycoprotein F stabilised in the prefusion conformation</p><p><sup>2</sup>produced in Chinese Hamster Ovary cells by recombinant DNA technology.</p><p><em>&nbsp;</em></p><p>The other ingredients are:</p><p><u>Powder</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trometamol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trometamol hydrochloride</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sucrose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mannitol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; polysorbate 80</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sodium chloride</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hydrochloric acid</p><p><u>Solvent</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Abrysvo is provided as
•	a white powder in a glass vial 
•	a solvent in a pre-filled syringe or a vial to dissolve the powder
After dissolving the powder in the solvent, the solution is clear and colourless.
Abrysvo is available in
•	a carton containing 1 vial of powder, 1 pre-filled syringe of solvent, 1 vial adaptor, with 1 needle or without needles (1 dose pack).
•	a carton containing 5 vials of powder, 5 pre-filled syringes of solvent, 5 vial adaptors, with 5 needles or without needles (5 dose pack).
•	a carton containing 10 vials of powder, 10 pre-filled syringes of solvent, 10 vial adaptors, with 10 needles or without needles (10 dose pack).
•	a carton containing 5 vials of powder and 5 vials of solvent (5 dose pack).
•	a carton containing 10 vials of powder and 10 vials of solvent (10 dose pack).

Not all pack sizes/types may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Pfizer Europe MA EEIG</p><p>Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Pfizer Manufacturing Belgium NV</p><p>Puurs-Sint-Amands</p><p>Belgium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 August 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">أبريسفو هو لقاح لمنع الإصابة بأمراض الرئتين (مجرى التنفس) التي يسببها فيروس يسمى الفيروس المخلوي التنفسي (RSV). يُعطَى أبريسفو إلى:</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحوامل لحماية الرضع منذ الولادة وحتى عمر ٦ أشهر</p><p dir="RTL">أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأفراد البالغين من العمر ٦۰ عامًا فأكبر.</p><p>&nbsp;</p><p dir="RTL">الفيروس المخلوي التنفسي هو فيروس شائع يسبب في معظم الحالات ظهور أعراض خفيفة تشبه البرد مثل التهاب الحلق، أو السعال، أو انسداد الأنف. ومع ذلك يمكن أن يسبب الفيروس المخلوي التنفسي حدوث مشكلات خطيرة بالرئتين لدى الرضع الصغار. ويمكن للفيروس أن يؤدي إلى تفاقم الأمراض مثل مرض الانسداد الرئوي المزمن (COPD) وفشل القلب الاحتقاني (CHF) عند كبار السن والأشخاص الذين يعانون من حالات طبية مزمنة. قد يؤدي الفيروس المخلوي التنفسي إلى الاحتجاز بالمستشفى في الحالات الشديدة، ويمكن أن يصبح مميتًا في بعض الحالات.</p><p>&nbsp;</p><p dir="RTL"><strong>آلية عمل أبريسفو</strong></p><p dir="RTL">يساعد هذا اللقاح الجهاز المناعي (وسائل الدفاع الطبيعية في الجسم) على صنع أجسام مضادة (مواد موجودة في الدم تساعد الجسم على مكافحة العدوى)، مما يحمي من الإصابة بأمراض الرئتين التي يسببها الفيروس المخلوي التنفسي. في حالة الحوامل اللاتي يتلقين اللقاح فيما بين الأسبوعين رقم ۲٤ و۳٦ من الحمل، تمر هذه الأجسام المضادة إلى الأجنة عبر المشيمة قبل الولادة، وهي تحميهم عندما يكونون أكثر عرضة لخطر الإصابة بالفيروس المخلوي التنفسي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;لا ينبغي إعطاء أبريسفو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه المواد الفعالة أو أي من المكونات الأخرى لهذا اللقاح (المدرجة في القسم ٦).</p><p>&nbsp;</p><p dir="RTL">تحذيرات واحتياطات</p><p dir="RTL">تحدث إلى طبيبك، أو الصيدلي، أو الممرضة قبل إعطائك هذا اللقاح</p><ul><li dir="RTL">إذا سبق أن تعرضت لتفاعل حساسية شديد أو مشكلات في التنفس بعدما تلقيت أي جرعة حقن من لقاح آخر أو بعد إعطائك أبريسفو في الماضي.</li><li dir="RTL">إذا كنت تشعر بالتوتر بشأن تلقي اللقاح أو سبق أن أغمي عليك بعد تلقي أي جرعة حقن. ويمكن أن يحدث الإغماء قبل أو بعد تلقي[RWS1]&nbsp; أي جرعة حقن</li><li dir="RTL">إذا كنت مصابًا بعدوى مصحوبة بحمى شديدة. وإذا كان الأمر كذلك، فحينئذٍ سيتم تأجيل تلقي اللقاح. لا داعي لتأجيل تلقي اللقاح في حالات الإصابة بعدوى طفيفة، مثل البرد، لكن تحدث إلى طبيبك أولًا.</li><li dir="RTL">إذا كنت تعاني من مشكلة متعلقة بالنزيف أو تصاب بالكدمات بسهولة.</li><li dir="RTL">إذا كنت تعاني من ضعف الجهاز المناعي، مما قد يمنع حصولك على الاستفادة الكاملة من أبريسفو.</li><li dir="RTL">إذا انقضى على فترة حملكِ أقل من ۲٤ أسبوعًا.</li></ul><p>&nbsp;</p><p dir="RTL">إذا انطبق عليك أي مما ذُكر أعلاه (أو إذا لم تكن متأكدًا)، فتحدث إلى طبيبك، أو الصيدلي، أو الممرضة قبل إعطائك أبريسفو.</p><p>&nbsp;</p><p dir="RTL">كما هو الحال بالنسبة لأي لقاح، قد لا يوفر أبريسفو الحماية الكاملة لجميع من يتلقونه.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يوصى باستخدام أبريسفو مع الأطفال والشباب الذين تقل أعمارهم عن ۱۸ عامًا إلا خلال فترة الحمل (انظر قسم &quot;الحمل&quot; أدناه).</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وأبريسفو</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تستخدم، أو استخدمت مؤخرًا، أو قد تستخدم أي أدوية أخرى، أو تلقيت مؤخرًا أي لقاح آخر.</p><p>&nbsp;</p><p dir="RTL">&nbsp;يمكن أن يُعطَى أبريسفو في نفس وقت إعطاء لقاح الإنفلونزا. يوصى بترك فاصل زمني لا يقل عن أسبوعين بين إعطاء أبريسفو وإعطاء اللقاح المضاد للكزاز، والدفتيريا، والشاهوق غير الخلوي (السعال الديكي).</p><p>&nbsp;</p><p dir="RTL">&nbsp;الحمل والرضاعة الطبيعية</p><p dir="RTL">يمكن إعطاء هذ اللقاح للحوامل في أواخر الثلث الثاني أو الثالث من الحمل (الأسبوع رقم ۲٤ إلى ۳٦). استشيري طبيبكِ أو الممرضة قبل تلقي هذا اللقاح إذا كنتِ ترضعين رضاعة طبيعية.</p><p>&nbsp;</p><p dir="RTL">القيادة واستخدام الآلات</p><p dir="RTL">من المستبعد أن يؤثر أبريسفو على قدرتك على القيادة أو استخدام الآلات.</p><p>&nbsp;</p><p dir="RTL"><strong>احتواء أبريسفو على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ۱ مليمول من الصوديوم (٢٣ ملجم) لكل جرعة، أي أنه يُعد &quot;خاليًا من الصوديوم&quot; بشكل أساسي.</p><p>&nbsp;</p><p>&nbsp;[RWS1]Comment from RWS : Please check the date in the source footer, it says &quot;December 2024&quot;. Currently translated as per source.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ستُعطى جرعة حقن واحدة مقدارها ٠٬٥ مل في عضلة بالجزء العلوي من ذراعك.</p><p>&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة حول استخدام أبريسفو، فاسأل طبيبك، أو الصيدلي، أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع اللقاحات، يمكن أن يسبب هذا اللقاح آثارًا جانبية، إلا أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الخطيرة</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة</strong>: (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰۰ شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة غيان باريه (اضطراب عصبي يبدأ عادة بالشعور بالشكشكة والوخز وضعف في الأطراف، وقد يتطور إلى شلل في جزء من الجسم أو في الجسم كله).</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة جدًا</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰۰۰ شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية - تتضمن العلامات التي تدل على الإصابة بتفاعل الحساسية تورم الوجه، أو الشفتين، أو اللسان، أو الحلق، والشرى، وصعوبة التنفس أو البلع، والدوار. انظر أيضًا القسم ۲.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور إذا لاحظت ظهور أي علامات تدل على الإصابة بهذه الآثار الجانبية الخطيرة.</p><p>&nbsp;</p><p dir="RTL"><strong>تم الإبلاغ عن الآثار الجانبية التالية لدى الحوامل</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بألم في موضع إعطاء جرعة الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم العضلي.</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار موضع إعطاء جرعة الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم موضع إعطاء جرعة الحقن.</p><p>&nbsp;</p><p dir="RTL">لم يتم الإبلاغ عن إصابة الرضع المولودين لأمهات تلقين اللقاح بأي آثار جانبية.</p><p>&nbsp;</p><p dir="RTL"><strong>تم الإبلاغ عن الآثار الجانبية التالية لدى الأفراد البالغين من العمر ٦٠ عامًا فأكبر</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بألم في موضع إعطاء جرعة الحقن</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار موضع إعطاء جرعة الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم موضع إعطاء جرعة الحقن.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة</strong>: (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰۰ شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة غيان باريه (انظر قسم &quot;الآثار الجانبية الخطيرة&quot; أعلاه).</p><p>&nbsp;</p><p dir="RTL"><strong>نادرة جدًا</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰۰۰ شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية (انظر قسم &quot;الآثار الجانبية الخطيرة&quot; أعلاه).</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أُصبت بأي آثار جانبية، فتحدث إلى طبيبك، أو الصيدلي، أو الممرضة. ويتضمن ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية:</strong></p><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:378px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong> (<strong>NPC</strong>)</p><p dir="RTL">مركز الاتصال: ۱۹۹۹۹</p><p dir="RTL">&nbsp;البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول مجلس التعاون لدول الخليج العربية (</strong><strong>GCC</strong><strong>) الأخرى</strong></p><p><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:378px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp; </em><em>يُرجى التواصل مع السلطات المختصة المعنية.</em></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُدون على العبوة الكرتونية والملصق، بعد الرمز EXP. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">يُخزَّن في الثلاجة (درجتان مئويتان - ۸ درجات مئوية).</p><p>&nbsp;</p><p dir="RTL">لا تجمده. وتخلص منه إذا جُمدت العبوة الكرتونية.</p><p>&nbsp;</p><p dir="RTL">بعد التحضير، ينبغي إعطاء أبريسفو على الفور أو في غضون ٤ ساعات في حالة تخزينه في درجة حرارة تتراوح بين ۱٥ درجة مئوية و۳۰ درجة مئوية. ولا تجمده.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة هي:</p><p dir="RTL">المستضد الاندماجي في شكل ما قبل الاندماج ذو الحالة المستقرة الذي يستهدف المجموعة الفرعية A بالفيروس المخلوي التنفسي<sup>&rlm;۲،۱</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٦۰ ميكروجرامًا</p><p dir="RTL">المستضد الاندماجي في شكل ما قبل الاندماج ذو الحالة المستقرة الذي يستهدف المجموعة الفرعية B بالفيروس المخلوي التنفسي<sup>&rlm;۲،۱</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٦۰ ميكروجرامًا</p><p dir="RTL">(مستضدات الفيروس المخلوي التنفسي)</p><p dir="RTL"><sup>۱</sup>البروتين السكري الاندماجي ذو الحالة المستقرة في هيئة ما قبل الاندماج</p><p dir="RTL"><sup>۲</sup>يُنتَج في خلايا مبيض الهامستر الصيني بتقنية الحمض النووي الريبوزي منقوص الأكسجين (DNA) المأشوب.</p><p>&nbsp;</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL"><u>المسحوق</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تروميتامول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيدروكلوريد التروميتامول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكروز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مانيتول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بولي سوربات ۸۰</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلوريد الصوديوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض الهيدروكلوريك</p><p dir="RTL"><u>المذيب</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ماء مخصص للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong></p><p dir="RTL">يتوفر أبريسفو في صورة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مسحوق أبيض في قارورة زجاجية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مذيب في محقنة مسبقة التعبئة أو قارورة لإذابة المسحوق</p><p dir="RTL">بعد إذابة المسحوق في المذيب، يظهر المحلول صافيًا وعديم اللون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبريسفو متوفر في</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة كرتونية تحتوي على قارورة واحدة بها مسحوق، محقنة واحدة مسبقة التعبئة بها مذيب، مهايئ واحد للقارورة، بالإضافة إلى إبرة واحدة أو دون إبر (عبوة تكفي جرعة واحدة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة كرتونية تحتوي على ٥ قوارير بها مسحوق، ٥ محاقن مسبقة التعبئة بها مذيب، ٥ مهايئات للقوارير، بالإضافة إلى ٥ إبر أو دون إبر(عبوة تكفي ٥ جرعات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة كرتونية تحتوي على ١٠ قوارير بها مسحوق، ١٠ محاقن مسبقة التعبئة بها مذيب، ١٠ مهايئات للقوارير، بالإضافة إلى ١٠ إبر أو دون إبر(عبوة تكفي ١٠ جرعات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة كرتونية تحتوي على ٥ قوارير بها مسحوق، و٥ قوارير بها مذيب (عبوة تكفي ٥ جرعات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة كرتونية تحتوي على ١٠ قوارير بها مسحوق، و١٠ قوارير بها مذيب (عبوة تكفي ١٠ جرعات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تُطرح جميع أحجام/أنواع العبوات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">فايزر يوروب إم أي إي إي جي، بلجيكا</p><p>&nbsp;</p><p><strong>الشركة الصانعة&rlm;</strong></p><p dir="RTL">فايزر مانفاكشرينج بيلجيم إن في بورس-سينت-اماندس، بلجيكا</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            اغسطس 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Abrysvo powder and solvent for solution for injection

Respiratory syncytial virus vaccine (bivalent, recombinant)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                After reconstitution, one dose (0.5 mL) contains:

RSV subgroup A stabilised prefusion F antigen1,2	60 micrograms
RSV subgroup B stabilised prefusion F antigen1,2	60 micrograms
(RSV antigens)
1glycoprotein F stabilised in the prefusion conformation
2produced in Chinese Hamster Ovary cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection.

The powder is white. 
The solvent is a clear, colourless liquid.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Abrysvo is indicated for:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Passive protection against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age following maternal immunisation during pregnancy. See sections 4.2 and 5.1.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by RSV.</p><p>&nbsp;</p><p>The use of this vaccine should be in accordance with official recommendations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p><em><u>Pregnant individuals</u></em></p><p>A single dose of 0.5&nbsp;mL should be administered between weeks 24 and 36 of gestation (see sections 4.4 and&nbsp;5.1).</p><p>&nbsp;</p><p><em><u>Individuals 60 years of age and older</u></em></p><p>A single dose of 0.5&nbsp;mL should be administered.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>The safety and efficacy of Abrysvo in children (from birth to less than 18 years of age) have not yet been established. Limited data are available in pregnant adolescents and their infants (see section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Abrysvo is for intramuscular injection into the deltoid region of the upper arm.</p><p>&nbsp;</p><p>The vaccine should not be mixed with any other vaccines or medicinal products.</p><p>&nbsp;</p><p>For instructions on reconstitution and handling of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p><u>&nbsp;</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Hypersensitivity and anaphylaxis</u></p><p><u>&nbsp;</u></p><p>Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.</p><p>&nbsp;</p><p><u>Anxiety-related reactions</u></p><p><u>&nbsp;</u></p><p>Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from fainting.</p><p>&nbsp;</p><p><u>Concurrent illness</u></p><p><u>&nbsp;</u></p><p>Vaccination should be postponed in individuals suffering from an acute febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.</p><p><u>&nbsp;</u></p><p><u>Thrombocytopenia and coagulation disorders</u></p><p><u>&nbsp;</u></p><p>Abrysvo should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding or bruising may occur following an intramuscular administration to these individuals.</p><p>&nbsp;</p><p><u>Immunocompromised individuals</u></p><p><u>&nbsp;</u></p><p>The efficacy and safety of the vaccine have not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of Abrysvo may be lower in immunosuppressed individuals.</p><p>&nbsp;</p><p><u>Individuals less than 24 weeks </u><u>of gestation</u></p><p><u>&nbsp;</u></p><p>Abrysvo has not been studied in pregnant individuals less than 24 weeks of gestation. Since protection of the infant against RSV depends on transfer of maternal antibodies across the placenta, Abrysvo should be administered between weeks 24 and 36 of gestation (see sections 4.2 and&nbsp;5.1).</p><p>&nbsp;</p><p><u>Limitations of vaccine effectiveness</u></p><p><u>&nbsp;</u></p><p>As with any vaccine, a protective immune response may not be elicited after vaccination.</p><p>&nbsp;</p><p><u>Excipient</u></p><p><u>&nbsp;</u></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Abrysvo can be administered concomitantly with seasonal influenza vaccine (QIV, surface antigen, inactivated, adjuvanted). In a randomised study in adults 65 years of age and older, the criteria for non‑inferiority of the immune responses in the co‑administration versus the separate administration group were met. However, numerically lower RSV&nbsp;A and&nbsp;B neutralising titres and numerically lower influenza&nbsp;A and&nbsp;B haemagglutination inhibition titres were observed when Abrysvo and inactivated adjuvanted seasonal influenza vaccine were co-administered than when they were administered separately. The clinical relevance of this finding is unknown.</p><p>&nbsp;</p><p>A minimum interval of two weeks is recommended between administration of Abrysvo and administration of a tetanus, diphtheria and acellular pertussis vaccine (Tdap). There were no safety concerns when Abrysvo was co-administered with Tdap in healthy non-pregnant women. Immune responses to RSV&nbsp;A, RSV&nbsp;B, diphtheria and tetanus on co-administration were non-inferior to those after separate administration. However, the immune responses to the pertussis components were lower on co-administration compared to separate administration and did not meet the criteria for non-inferiority. The clinical relevance of this finding is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>Data on pregnant women (more than 4&nbsp;000 exposed outcomes) indicate no malformative nor feto/neonatal toxicity.</p><p>&nbsp;</p><p>Results from animal studies with Abrysvo do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p>In a phase 3 study (Study 1), maternal adverse events reported within 1&nbsp;month after vaccination were similar in the Abrysvo group (14%) and the placebo group (13%).</p><p>&nbsp;</p><p>No safety signals were detected in infants up to 24&nbsp;months of age. The incidences of adverse events reported within 1&nbsp;month after birth in infants were similar in the Abrysvo group (37%) and the placebo group (35%). Major birth outcomes assessed in the Abrysvo group compared to placebo included premature birth (201 (6%) and 169 (5%), respectively), low birth weight (181 (5%) and 155 (4%), respectively) and congenital anomalies (174 (5%) and 203 (6%), respectively).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p>It is unknown whether Abrysvo is excreted in human milk. No adverse effects of Abrysvo have been shown in breastfed newborns of vaccinated mothers.</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>No human data on the effect of Abrysvo on fertility are available.</p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to female fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Abrysvo has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p><em><u>Pregnant individuals</u></em></p><p>In pregnant women at 24-36 weeks of gestation the most frequently reported adverse reactions were vaccination site pain (41%), headache (31%) and myalgia (27%). The majority of local and systemic reactions in maternal participants were mild to moderate in severity and resolved within 2-3 days of onset.</p><p>&nbsp;</p><p><em><u>Individuals 60 years of age and older</u></em></p><p>In individuals 60 years of age and older the most frequently reported adverse reaction was vaccination site pain (11%). The majority of reactions were mild to moderate in severity and resolved within 1‑2 days of onset.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The safety of administering a single dose of Abrysvo to pregnant women at 24-36 weeks of gestation (n=3&nbsp;682) and to individuals 60 years of age and older (n=18&nbsp;575) was evaluated in phase&nbsp;3 clinical trials.</p><p>&nbsp;</p><p>Adverse reactions are listed according to the following frequency categories:</p><p>Very common (&ge;1/10);</p><p>Common (&ge;1/100 to &lt;1/10);</p><p>Uncommon (&ge;1/1&nbsp;000 to &lt;1/100);</p><p>Rare (&ge;1/10&nbsp;000 to &lt;1/1&nbsp;000);</p><p>Very rare (&lt;1/10&nbsp;000);</p><p>Not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Adverse reactions reported are listed per system organ class, in decreasing order of seriousness.</p><p>&nbsp;</p><p><strong>Table 1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions following administration of Abrysvo</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:548px"><thead><tr><td style="vertical-align:top"><p>System organ class</p></td><td style="vertical-align:top"><p>Adverse drug reactions</p><p><strong>p</strong><strong>regnant i</strong><strong>ndividuals &le;49 years</strong></p></td><td style="vertical-align:top"><p>Adverse drug reactions</p><p><strong>individuals &ge;60 years</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p>Immune system disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Headache</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Guillain-Barr&eacute; syndrome</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Myalgia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Vaccination site pain</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Vaccination site redness</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Vaccination site swelling</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the National Pharmacovigilance Centre (NPC).</p><p>&nbsp;</p><p><strong>To report any side effects:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:354px"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>SFDA Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose with Abrysvo is unlikely due to its single dose presentation.</p><p>&nbsp;</p><p>There is no specific treatment for an overdose with Abrysvo. In the event of an overdose, the individual should be monitored and provided with symptomatic treatment as appropriate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Vaccines, other viral vaccines; ATC code: J07BX05</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Abrysvo contains two recombinant stabilised RSV prefusion F antigens representing subgroups RSV‑A and RSV‑B. Prefusion F is the primary target of neutralising antibodies that block RSV infection. Following intramuscular administration, the prefusion F antigens elicit an immune response, which protects against RSV‑associated lower respiratory tract disease.</p><p>&nbsp;</p><p>In infants born to mothers who were vaccinated with Abrysvo between weeks 24 and 36 of gestation, protection against RSV-associated lower respiratory tract disease is due to transplacental transfer of RSV neutralising antibodies. Adults 60 years of age and older are protected by active immunisation.</p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p><em><u>&nbsp;</u></em></p><p><em><u>Infants from birth through 6 months of age by active immunisation of pregnant individuals</u></em></p><p>Study 1 is a phase 3, multicentre, randomised (1:1), double-blind, placebo‑controlled study to assess the efficacy of a single dose of Abrysvo in the prevention of RSV‑associated lower respiratory tract disease in infants born to pregnant individuals vaccinated between weeks 24 and 36 of gestation. The need for revaccination with subsequent pregnancies has not been established.</p><p>&nbsp;</p><p>RSV-associated lower respiratory tract illness was defined as a medically attended visit with a reverse transcription-polymerase chain reaction (RT-PCR) confirmed RSV illness with one or more of the following respiratory symptoms: fast breathing, low oxygen saturation (SpO<sub>2</sub> &lt;95%) and chest wall indrawing. RSV-associated severe lower respiratory tract illness was defined as an illness that met the lower respiratory tract illness‑RSV criteria plus at least one of the following: very fast breathing, low oxygen saturation (SpO<sub>2</sub> &lt;93%), high-flow oxygen supplementation via nasal cannula or mechanical ventilation, ICU admission for &gt;4&nbsp;hours and/or failure to respond/unconscious.</p><p>&nbsp;</p><p>In this study, 3&nbsp;695 pregnant individuals with uncomplicated, singleton pregnancies were randomised to the Abrysvo group and 3&nbsp;697 to placebo.</p><p>Vaccine efficacy (VE) was defined as the relative risk reduction of the endpoint in the Abrysvo group compared to the placebo group for infants born to pregnant individuals who received the assigned intervention. There were two primary efficacy endpoints, assessed in parallel, severe RSV‑positive medically attended lower respiratory tract illness and RSV‑positive medically attended lower respiratory tract illness, occurring within 90, 120, 150 or 180 days after birth.</p><p>&nbsp;</p><p>Of the pregnant women who received Abrysvo, 65% were White, 20% were Black or African American and 29% were Hispanic/Latino. The median age was 29 years (range 16‑45 years); 0.2% of participants were under 18 years of age and 4.3% were under 20 years of age. The median gestational age at vaccination was 31 weeks and 2 days (range 24 weeks and 0 days to 36 weeks and 4 days). The median infant gestational age at birth was 39 weeks and 1 day (range 27 weeks and 3 days to 43 weeks and 6 days).</p><p>&nbsp;</p><p>Vaccine efficacy is presented in Tables 2 and 3.</p><p>&nbsp;</p><p><strong>Table 2&nbsp; Vaccine efficacy of Abrysvo against severe medically attended lower respiratory tract illness caused by RSV</strong><strong> in i</strong><strong>nfants from birth through 6&nbsp;months of age by active immunisation of pregnant individuals &ndash; Study&nbsp;1</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>Time period</p></td><td style="vertical-align:top"><p>Abrysvo</p><p>Number of cases</p><p><strong>N=3&nbsp;495</strong></p></td><td style="vertical-align:top"><p>Placebo</p><p>Number of cases</p><p><strong>N=3&nbsp;480</strong></p></td><td style="vertical-align:top"><p>VE %</p><p>(CI)<sup>a</sup></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>90 days</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>81.8 (40.6, 96.3)</p></td></tr><tr><td style="vertical-align:top"><p>120 days</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>73.9 (45.6, 88.8)</p></td></tr><tr><td style="vertical-align:top"><p>150 days</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>55</p></td><td style="vertical-align:top"><p>70.9 (44.5, 85.9)</p></td></tr><tr><td style="vertical-align:top"><p>180 days</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>62</p></td><td style="vertical-align:top"><p>69.4 (44.3, 84.1)</p></td></tr></tbody></table><p>CI = confidence interval; VE = vaccine efficacy</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; 99.5% CI at 90 days; 97.58% CI at later intervals</p><p>&nbsp;</p><p><strong>Table 3&nbsp; Vaccine efficacy of Abrysvo against medically attended lower respiratory tract illness caused by RSV</strong><strong> in </strong><strong>infants from birth through 6&nbsp;months of age by active immunisation of pregnant individuals - Study 1</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>Time period</p></td><td style="vertical-align:top"><p>Abrysvo</p><p>Number of cases</p><p><strong>N=3&nbsp;495</strong></p></td><td style="vertical-align:top"><p>Placebo</p><p>Number of cases</p><p><strong>N=3&nbsp;480</strong></p></td><td style="vertical-align:top"><p>VE %</p><p>(CI)<sup>a</sup></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>90 days</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>56</p></td><td style="vertical-align:top"><p>57.1 (14.7, 79.8)</p></td></tr><tr><td style="vertical-align:top"><p>120 days</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>81</p></td><td style="vertical-align:top"><p>56.8 (31.2, 73.5)</p></td></tr><tr><td style="vertical-align:top"><p>150 days</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>99</p></td><td style="vertical-align:top"><p>52.5 (28.7, 68.9)</p></td></tr><tr><td style="vertical-align:top"><p>180 days</p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>117</p></td><td style="vertical-align:top"><p>51.3 (29.4, 66.8)</p></td></tr></tbody></table><p>CI = confidence interval; VE = vaccine efficacy</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; 99.5% CI at 90 days; 97.58% CI at later intervals</p><p>&nbsp;</p><p>A post-hoc analysis of VE by maternal gestational age was conducted. For severe medically attended lower respiratory tract illness occurring within 180 days, VE was 57.2% (95% CI 10.4, 80.9) for women vaccinated early in pregnancy (24 to &lt;30 weeks) and 78.1% (95% CI 52.1, 91.2) for women vaccinated later in the pregnancy eligible window (30 to 36 weeks). For medically attended lower respiratory tract illness occurring within 180 days, VE was 30.9% (95% CI -14.4, 58.9) for women vaccinated early in pregnancy (24 to &lt;30 weeks) and 62.4% (95% CI 41.6, 76.4) for women vaccinated later in the pregnancy eligible window (30 to 36 weeks).</p><p>&nbsp;</p><p><em><u>Active immunisation of individuals 60 years of age and older</u></em></p><p>Study 2 is a phase 3, multicentre, randomised, double‑blind, placebo-controlled study to assess the efficacy of Abrysvo in the prevention of RSV‑associated lower respiratory tract illness in individuals 60&nbsp;years of age and older.</p><p>&nbsp;</p><p>RSV-associated lower respiratory tract illness was defined as RT‑PCR confirmed RSV illness with two or more or three or more of the following respiratory symptoms within 7 days of symptom onset and lasting more than 1 day during the same illness: new or increased cough, wheezing, sputum production, shortness of breath or tachypnoea (&ge;25 breaths/min or 15% increase from resting baseline).</p><p>&nbsp;</p><p>Participants were randomised (1:1) to receive Abrysvo (n=18&nbsp;488) or placebo (n=18&nbsp;479). Enrollment was stratified by age 60-69 years (63%), 70-79 years (32%) and &ge;80&nbsp;years (5%). Subjects with stable chronic underlying conditions were eligible for this study and 52% of participants had at least 1 prespecified condition; 16% of participants were enrolled with stable chronic cardiopulmonary conditions such as asthma (9%), chronic obstructive pulmonary disease (7%) or congestive heart failure (2%). Immunocompromised individuals were ineligible.</p><p>&nbsp;</p><p>The primary objective was assessment of vaccine efficacy (VE), defined as the relative risk reduction of first episode of RSV-associated lower respiratory tract illness in the Abrysvo group compared to the placebo group in the first RSV season.</p><p>&nbsp;</p><p>Of the participants who received Abrysvo, 51% were male and 80% were White, 12% were Black or African American and 41% were Hispanic/Latino. The median age of participants was 67 years (range 59‑95 years).</p><p>&nbsp;</p><p>At the end of the first RSV season the analysis demonstrated statistically significant efficacy for Abrysvo for reduction of RSV-associated lower respiratory tract illness with &ge;2&nbsp;symptoms and with &ge;3 symptoms.</p><p>&nbsp;</p><p>Vaccine efficacy information is presented in Table 4.</p><p>&nbsp;</p><p><strong>Table 4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaccine efficacy of Abrysvo against RSV disease - active immunisation of individuals 60&nbsp;years of age and older &ndash; Study 2</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>Efficacy endpoint</p></td><td style="vertical-align:top"><p>Abrysvo</p><p>Number of cases</p><p><strong>N=18&nbsp;058</strong></p></td><td style="vertical-align:top"><p>Placebo</p><p>Number of cases</p><p><strong>N=18&nbsp;076</strong></p></td><td style="vertical-align:top"><p>VE (%)</p><p>(95% CI)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>First episode of RSV-associated lower respiratory tract illness with &ge;2 symptoms<sup>a</sup></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>65.1 (35.9, 82.0)</p></td></tr><tr><td style="vertical-align:top"><p>First episode of RSV-associated lower respiratory tract illness with &ge;3 symptoms<sup>b</sup></p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>88.9 (53.6, 98.7)</p></td></tr></tbody></table><p>CI &ndash; confidence interval; RSV &ndash; respiratory syncytial virus; VE &ndash; vaccine efficacy<sup> </sup></p><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>In an exploratory analysis in RSV subgroup A (Abrysvo n=3, placebo n=16 VE was 81.3% (CI 34.5, 96.5); and in RSV subgroup B (Abrysvo n=12, placebo n=26) VE was 53.8% (CI 5.2, 78.8).</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>In an exploratory analysis in RSV subgroup A (Abrysvo n=1, placebo n=5) VE was 80.0% (CI -78.7, 99.6); and in RSV subgroup B (Abrysvo n=1, placebo n=12) VE was 91.7% (CI 43.7, 99.8).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Abrysvo in children from 2 to less than 18 years of age in prevention of lower respiratory tract disease caused by RSV (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity and toxicity to reproduction and development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Powder</u></p><p><u>&nbsp;</u></p><p>Trometamol</p><p>Trometamol hydrochloride</p><p>Sucrose</p><p>Mannitol</p><p>Polysorbate 80</p><p>Sodium chloride</p><p>Hydrochloric acid (for pH adjustment)</p><p>&nbsp;</p><p><u>Solvent</u></p><p><u>&nbsp;</u></p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years

The unopened vial is stable for 5 days when stored at temperatures from 8°C to 30°C. At the end of this period Abrysvo should be used or discarded. This information is used to guide healthcare professionals in case of temporary temperature excursions only.

After reconstitution

Abrysvo should be administered immediately after reconstitution or within 4 hours if stored between 15°C and 30°C. Do not freeze.

Chemical and physical in-use stability has been demonstrated for 4 hours between 15°C and 30°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in use storage times and conditions prior to use are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&ordm;C - 8&ordm;C).</p><p>&nbsp;</p><p>Do not freeze. Discard if the carton has been frozen.</p><p>&nbsp;</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Vial of antigens for Abrysvo (powder) and pre-filled syringe of solvent</u></p><p><u>&nbsp;</u></p><p>Powder for 1 dose in a vial (type 1 glass or equivalent) with a stopper (synthetic chlorobutyl rubber) and a flip off cap</p><p>&nbsp;</p><p>Solvent for 1 dose in a pre-filled syringe (type 1 glass) with a stopper (synthetic chlorobutyl rubber) and a tip cap (synthetic isoprene/bromobutyl blend rubber)</p><p><u>&nbsp;</u></p><p>Vial adaptor</p><p>&nbsp;</p><p><u>Vial of antigens for Abrysvo (powder) and vial of solvent</u></p><p>&nbsp;</p><p>Powder for 1 dose in a vial (type 1 glass or equivalent) with a stopper (synthetic chlorobutyl rubber) and a flip off cap</p><p>&nbsp;</p><p>Solvent for 1 dose in a vial (type 1 glass or equivalent) with a stopper (bromobutyl rubber) and a flip off cap</p><p>&nbsp;</p><p><u>Pack sizes</u></p><p><u>&nbsp;</u></p><p>Pack containing 1 vial of powder (antigens), 1 pre-filled syringe of solvent, 1 vial adaptor with 1&nbsp;needle or without needles (1 dose pack).</p><p>Pack containing 5 vials of powder (antigens), 5 pre-filled syringes of solvent, 5 vial adaptors with 5&nbsp;needles or without needles (5 dose pack).</p><p>Pack containing 10 vials of powder (antigens), 10 pre-filled syringes of solvent, 10 vial adaptors with 10&nbsp;needles or without needles (10 dose pack).</p><p>Pack containing 5&nbsp;vials of powder (antigens) and 5&nbsp;vials of solvent (5 dose pack).</p><p>Pack containing 10&nbsp;vials of powder (antigens) and 10&nbsp;vials of solvent (10 dose pack).</p><p>&nbsp;</p><p>Not all pack sizes/types may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>For use of vial of antigens for Abrysvo (powder), pre-filled syringe of solvent and vial adaptor</u></p><p>&nbsp;</p><p>Abrysvo must be reconstituted prior to administration by adding the entire contents of the pre‑filled syringe of solvent to the vial containing the powder using the vial adaptor.</p><p>&nbsp;</p><p>The vaccine must be reconstituted only with the solvent provided.</p><p>&nbsp;</p><p><em>Preparation for administration</em></p><p><u>&nbsp;</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td colspan="2"><p><strong>Pre-filled </strong><strong>syringe containing solvent for Abrysvo</strong></p></td><td><p><strong>Vial </strong><strong>containing antigens for Abrysvo (powder)</strong></p></td><td colspan="2"><p><strong>Vial adaptor</strong></p></td></tr><tr><td colspan="2"><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
   coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
   filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_40" o:spid="_x0000_i1030" type="#_x0000_t75"
   style='width:222.75pt;height:78pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image001.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="297" height="104" src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image002.jpg" /></p></td><td><p><!--[if gte vml 1]><v:shape id="Picture_x0020_41"
   o:spid="_x0000_i1029" type="#_x0000_t75" style='width:108pt;height:84.75pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image003.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="144" height="113" src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image004.jpg" /></p></td><td colspan="2"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_42"
   o:spid="_x0000_i1028" type="#_x0000_t75" style='width:56.25pt;height:58.5pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image005.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="75" height="78" src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image006.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p>Syringe cap</p></td><td style="vertical-align:top"><p>Luer lock adaptor</p></td><td colspan="2" style="vertical-align:top"><p>Vial stopper (with flip off cap removed)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:686px"><tbody><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_2" o:spid="_x0000_i1027"
   type="#_x0000_t75" style='width:96pt;height:96pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image007.png"
    o:title=""/>
  </v:shape><![endif]--><img width="128" height="128" src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image008.gif" /></p></td><td style="vertical-align:top"><p><strong>Step 1. Attach vial adaptor</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peel off the top cover from the vial adaptor packaging and remove the flip off cap from the vial.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; While keeping the vial adaptor in its packaging, centre over the vial&rsquo;s stopper and connect with a straight downward push. Do not push the vial adaptor in at an angle as it may result in leaking. Remove the packaging.</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:686px"><tbody><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_5"
   o:spid="_x0000_i1026" type="#_x0000_t75" style='width:95.25pt;height:95.25pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image009.png"
    o:title=""/>
  </v:shape><![endif]--><img width="127" height="127" src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image010.gif" /></p></td><td style="vertical-align:top"><p><strong>Step 2. Reconstitute the powder component (antigens) to form Abrysvo</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For all syringe assembly steps, hold the syringe only by the Luer lock adaptor. This will prevent the Luer lock adaptor from detaching during use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Twist to remove the syringe cap, then twist to connect the syringe to the vial adaptor. Stop turning when you feel resistance.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inject the entire contents of the syringe into the vial. Hold the plunger rod down and gently swirl the vial until the powder is completely dissolved (approximately 1‑2 minutes). Do not shake.</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:686px"><tbody><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_7"
   o:spid="_x0000_i1025" type="#_x0000_t75" style='width:94.5pt;height:94.5pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image011.jpg"
    o:title=""/>
  </v:shape><![endif]--><img width="126" height="126" src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image012.jpg" /></p></td><td style="vertical-align:top"><p><strong>Step 3. Withdraw reconstituted vaccine</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Invert the vial completely and slowly withdraw the entire contents into the syringe to ensure a 0.5&nbsp;mL dose of Abrysvo.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Twist to disconnect the syringe from the vial adaptor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Attach a sterile needle suitable for intramuscular injection.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p>The prepared vaccine is a clear and colourless solution. Visually inspect the vaccine for large particulate matter and discolouration prior to administration. Do not use if large particulate matter or discolouration is found.</p><p><u>&nbsp;</u></p><p><u>For use of vial of antigens for Abrysvo (powder) and vial of solvent</u></p><p><u>&nbsp;</u></p><p>The vial containing antigens for Abrysvo (powder) must be reconstituted only with the vial of solvent provided to form Abrysvo.</p><p><em>&nbsp;</em></p><p><em>Preparation for administration</em></p><p><em>&nbsp;</em></p><p>1.&nbsp;&nbsp;&nbsp; Using a sterile needle and sterile syringe, withdraw the entire contents of the vial containing the solvent and inject the entire contents of the syringe into the vial containing the powder.</p><p>2.&nbsp;&nbsp;&nbsp; Gently swirl the vial in a circular motion until the powder is completely dissolved. Do not shake.</p><p>3.&nbsp;&nbsp;&nbsp; Withdraw 0.5&nbsp;mL from the vial containing the reconstituted vaccine.</p><p>The prepared vaccine is a clear and colourless solution. Visually inspect the vaccine for large particulate matter and discolouration prior to administration. Do not use if large particulate matter or discolouration is found.</p><p>&nbsp;</p><p><u>Disposal</u></p><p><u>&nbsp;</u></p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pfizer Europe MA EEIG
Belgium

MANUFACTURED BY
Pfizer Manufacturing Belgium NV
Puurs-Sint-Amands
Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>